Mercado de testes de ponto de cuidado molecular de África (utilizando NAAT), por produto (instrumentos e consumíveis e reagentes), indicação (testes de infeções respiratórias, testes de infeções sexualmente transmissíveis (IST) , testes de infeções do trato gastrointestinal e outros) , utilizador final (laboratórios, Hospitais, clínicas, centros de ambulatório, cuidados domiciliários, instalações de vida assistida e outros), modo de teste (testes baseados em prescrição e testes OTC), canal de distribuição (farmácia hospitalar, farmácia de retalho e farmácia on -line) - tendências do setor e previsão para 2028 .
Análise de mercado e insights de testes de ponto de atendimento molecular de África (utilizando NAAT)
Espera-se que o mercado de testes moleculares no ponto de atendimento de África (utilizando o NAAT) cresça devido à melhoria das instalações e infraestruturas de saúde e à adoção de testes no ponto de atendimento em hospitais, laboratórios e clínicas, o que poderá impulsionar a desenvolvimento do mercado. Os outros fatores previstos para impulsionar o crescimento do mercado de testes moleculares de ponto de atendimento (utilizando NAAT) incluem a crescente prevalência de doenças infeciosas .
Os outros factores, como a falta de profissionais qualificados e o elevado custo dos testes moleculares personalizados no ponto de atendimento (utilizando o NAAT), dificultam o crescimento do mercado africano de testes moleculares no ponto de atendimento (utilizando o NAAT). Por outro lado, o aumento das despesas com cuidados de saúde e os países emergentes com hospitais desenvolvidos funcionam como uma oportunidade para fazer crescer o mercado africano de testes moleculares de cuidados de saúde (utilizando o NAAT).
A Data Bridge Market Research analisa que o mercado africano de testes moleculares de ponto de cuidado (utilizando NAAT) crescerá a um CAGR de 5,8% de 2021 a 2028.
Métrica de reporte |
Detalhes |
Período de previsão |
2021 a 2028 |
Ano base |
2020 |
Anos históricos |
2019 |
Unidades Quantitativas |
Receita em milhões de dólares, preços em dólares |
Segmentos cobertos |
Por produto (instrumentos, consumíveis e reagentes), indicação (testes de infeções respiratórias, testes de infeções sexualmente transmissíveis (IST), testes de infeções do trato gastrointestinal e outros), utilizador final (laboratórios, hospitais, clínicas, centros de ambulatório, cuidados domiciliários , instalações de vida assistida e outros), modo de teste (testes baseados em prescrição e testes OTC), canal de distribuição (farmácia hospitalar, farmácia de retalho e farmácia online) |
Países abrangidos |
África do Sul, Quénia, Nigéria e Resto de África |
Participantes do mercado abrangidos |
Abbott, F.Hoffmann-La Roche Ltd., Danaher, Thermo Fisher Scientific Inc, Sysmex Corporation, Meridian Bioscience, BD, Biomérieux Sa, Qiagen, Quidel Corporation, Bio-Rad Laboratories, Inc., PerkinElmer Inc. |
Definição do mercado do mercado África Molecular Point of Care Testing (utilizando NAAT)
O POCT é caracterizado como um exame que pode ser realizado perto do paciente, onde uma decisão médica pode ser tomada de imediato, incluindo resultados e monitorização. Os dispositivos POCT que entram agora em uso clínico baseiam-se em tecnologias de amplificação de ácidos nucleicos (NAAT), aqui definidas como dispositivos de segunda geração. Estas plataformas apresentam geralmente uma sensibilidade melhorada, normalmente de 60 a 90%, em comparação com os POCT de primeira geração, e requerem instrumentação portátil com uma área útil de aproximadamente 30 cm x 30 cm. Estes instrumentos são essencialmente utilizados na deteção molecular de vários distúrbios, como o VIH, o HPV e as doenças respiratórias, através da tecnologia NAAT. Os NAAT são técnicas de amplificação de ácidos nucleicos que permitem a identificação de organismos patogénicos através da deteção do seu ADN ou ARN.
Na pandemia mundial, tentativa de sinergizar a sensibilidade dos NAATs e a facilidade de utilização dos ensaios POCT, dispositivos e ensaios POCT miniaturizados baseados em NAAT foram concebidos para triagem e diagnóstico mais rápidos do COVID-19, o que também impulsionou o crescimento do mercado.
Dinâmica de mercado dos testes moleculares de ponto de cuidado de África (utilizando o NAAT)
Esta secção trata da compreensão dos impulsionadores do mercado, vantagens, oportunidades, restrições e desafios. Tudo isto é discutido em detalhe abaixo:
Motoristas
- AUMENTAR A PREVALÊNCIA DE DOENÇAS CRÓNICAS
É um facto comum que a degeneração da saúde começa com o aumento da idade. À medida que a taxa de doenças crónicas aumenta com o tempo, aumentam também os factores associados às taxas de doença. O elevado número de população obesa/com excesso de peso aumentou também a prevalência de doenças crónicas em várias regiões do globo. O aumento do número de doenças crónicas semelhantes ao HPV, às IST e à TB, entre outras, levou as pessoas a optarem por pontos de atendimento baseados em NAAT e por produtos para testes. Portanto, isto pode impulsionar o crescimento do mercado africano de testes de ponto de atendimento molecular (utilizando NAAT) nos próximos anos.
- MELHORIA DA TAXA DE PROCURA DE DIAGNÓSTICO
Com o aumento do sucesso do diagnóstico de doenças crónicas, incluindo cancro, anemia, diabetes tipo 2, entre outras, os melhores profissionais de saúde proporcionam sessões regulares de formação aos profissionais para a realização de exames tendo em conta a melhoria da taxa de diagnóstico na região. Com o aumento da carga de doença, a taxa de diagnóstico também aumenta. Com os avanços no diagnóstico, o índice cresce também para as pessoas que passam pelo diagnóstico.
- AUMENTAR A PREFERÊNCIA PARA O TESTE DOMICILIAR
As preferências de cuidados de saúde ao domicílio disponibilizam informações clínicas no local e no momento certos. Ajudará também a reduzir erros e a aumentar a segurança com qualidade garantida. Também ajudam os idosos em caso de emergência médica. Foram feitas muitas mudanças estratégicas nos cuidados de saúde para abordar os benefícios dos testes no local de prestação de cuidados. De acordo com a Organização Mundial de Saúde (OMS), o número de pessoas com 65 ou mais anos deverá aumentar de cerca de 524 milhões em 2010 para aproximadamente 1,5 mil milhões em 2050, sendo os países desenvolvidos responsáveis pela maior parte do aumento.
Oportunidades
- INICIATIVAS ESTRATÉGICAS TOMADAS PELOS INTERVENIENTES DO MERCADO
O aumento do fardo das doenças crónicas e não crónicas a nível mundial, juntamente com o aumento da população geriátrica em África e na Ásia, criou mais procura para o desenvolvimento de novos kits e soluções para testes moleculares no local de cuidados com melhor eficácia e menos consumo de tempo. Para proporcionar o diagnóstico e rastreio nesta região, os intervenientes no mercado estabelecem parcerias e acordos entre si para prestar cuidados de qualidade através de kits e instrumentos à população africana.
- Despesas com a saúde Rise
O aumento dos gastos e da infraestrutura com saúde pode ajudar os pacientes a realizar tratamentos avançados sem complicações para receber melhores diagnósticos, procedimentos e tratamento para uma recuperação rápida. Os dispositivos de teste no local de atendimento são benéficos para detetar várias doenças e apoiar os planos de tratamento utilizando software e soluções POC. As despesas com cuidados de saúde incluem pagamentos diretos (pessoas que pagam os seus cuidados), despesas governamentais e fontes que incluem seguros de saúde e atividades de organizações não governamentais.
Restrições/Desafios
- ALTO CUSTO DOS PRODUTOS
Os produtos de teste no local de atendimento requerem um custo considerável para o processo de desenvolvimento. Como o conceito precisa de ser definido, os materiais devem ser adquiridos e é essencial considerar os prazos de entrega. Além disso, o processo é demorado, uma vez que o design do dispositivo precisa de tempo suficiente para amadurecer completamente antes de ser lançado no mercado para utilização.
- FALTA DE ALINHAMENTO COM OS RESULTADOS DOS TESTES OBTIDOS EM LABORATÓRIOS
Quando comparados com os resultados dos padrões de testes laboratoriais, os resultados dos testes NAAT diferem. Os testes laboratoriais são mais avançados, seguem o processo, o protocolo e a ciência dos testes laboratoriais e integram-se totalmente com a tecnologia necessária para analisar, validar e documentar os efeitos com precisão. No entanto, o POCT/NAAT está, sem dúvida, associado à falta de resultados precisos. O POCT molecular não consegue completar a padronização e outros critérios críticos não conseguem alcançar a padronização e diferentes padrões essenciais. É um desafio significativo para o mercado africano de testes moleculares de ponto de atendimento. Os testes PoC podem, por vezes, fornecer resultados erróneos e sofrer variabilidade nos resultados dos testes.
Impacto pós-COVID-19 no mercado de testes moleculares de ponto de cuidado de África (utilizando NAAT)
O COVID-19 impactou significativamente o mercado de testes moleculares de ponto de atendimento (utilizando o NAAT). A COVID-19 afetou positivamente o preço e a procura de produtos de testes moleculares no ponto de atendimento (utilizando NAAT) a um nível mais elevado devido às vendas online progressivas e aos avanços tecnológicos. O surto pandémico COVID-19 impactou positivamente o crescimento do mercado devido ao aumento da exigência de testes moleculares de ponto de atendimento (utilizando NAAT), especialmente em vários hospitais. A prioridade atual na maioria dos hospitais é dada aos tratamentos da COVID-19, uma vez que o aumento de casos de COVID-19 ainda é persistente, o que também aumenta a utilização de testes moleculares no ponto de atendimento (utilizando NAAT). Além disso, muitos governos internacionais e organizações de saúde apoiaram o fornecimento destes produtos devido à sua elevada prioridade em casos cruciais.
Desenvolvimentos recentes
- Em novembro de 2021, a F.Hoffmann-La Roche Ltd anunciou que a Roche foi classificada como uma das três empresas de saúde mais sustentáveis nos Índices Dow Jones de Sustentabilidade pelo décimo terceiro ano. Isto aumentou a capacidade de fazer negócios e a expansão dos negócios no período de previsão
- Em outubro de 2021, a Thermo Fisher Scientific Corporation recebeu a aprovação da FDA para o ensaio molecular SARS-COV do teste TaqMan COVId-19. Isto aumentou o portefólio de produtos da empresa e contribuiu para a receita da empresa no período de previsão
Âmbito do mercado de testes moleculares de ponto de cuidado de África (utilizando NAAT)
O mercado de testes moleculares de ponto de atendimento de África (utilizando o NAAT) está categorizado em cinco segmentos notáveis com base no produto, indicação, utilizador final, modo de teste e canal de distribuição. O crescimento entre estes segmentos ajudará a analisar os segmentos de crescimento do mercado nas indústrias e fornecerá aos utilizadores uma valiosa visão geral do mercado e informações de mercado para os ajudar a tomar decisões estratégicas para identificar as principais aplicações do mercado.
Produto
- Instrumentos
- Consumíveis e Reagentes
Com base no produto, o mercado de testes moleculares de ponto de cuidado de África (utilizando NAAT) está segmentado em instrumentos e consumíveis e reagentes.
Indicação
- Teste de infeção sexualmente transmissível (IST)
- Teste de infeção respiratória
- Teste de infeção do trato gastrointestinal
- Outros
Com base na indicação, o mercado africano de testes moleculares de atendimento (utilizando NAAT) está segmentado em testes de infeções sexualmente transmissíveis (IST), testes de infeções respiratórias, testes de infeções do trato gastrointestinal, entre outros.
Utilizador final
- Laboratórios
- Hospitais
- Clínicas
- Centros Ambulatórios
- Cuidados Domiciliários
- Instalações de vida assistida
- Outros
Com base no utilizador final, o mercado de testes moleculares de ponto de atendimento de África (utilizando NAAT) está segmentado em laboratórios, hospitais, clínicas, centros de ambulatório, cuidados domiciliários, instalações de vida assistida, entre outros.
Modo de teste
- Testes baseados na prescrição
- Teste OTC
Com base no modo de teste, o mercado africano de testes moleculares de ponto de atendimento (utilizando NAAT) está segmentado em testes baseados em prescrição e testes OTC .
Canal de distribuição
- Farmácia Hospitalar
- Farmácia de Retalho
- Farmácia on-line
Com base no canal de distribuição, o mercado africano de testes de ponto de atendimento molecular (utilizando NAAT) está segmentado em farmácia hospitalar, farmácia de retalho e farmácia online.
Testes Moleculares de Pontos de Cuidado de África (utilizando o NAAT) Análise/Insights Regionais de Mercado
O mercado de testes moleculares de ponto de atendimento de África (utilizando NAAT) é analisado, e são fornecidos insights e tendências de tamanho de mercado com base no produto, indicação, utilizador final, modo de teste e canal de distribuição.
O relatório de mercado de testes de ponto molecular de cuidado de África (utilizando NAAT) abrange a África do Sul, o Quénia, a Nigéria e o resto de África.
A África do Sul domina o mercado africano de testes de ponto de cuidado molecular (utilizando NAAT) com um CAGR de cerca de 6,1% em termos de quota de mercado e receitas de mercado. Continuará a florescer o seu domínio durante o período de previsão. Isto deve-se à crescente prevalência de doenças infeciosas e crónicas e aos crescentes avanços tecnológicos no setor da saúde.
Cenário competitivo e testes moleculares de pontos de atendimento em África (utilizando o NAAT) Análise da quota de mercado
O panorama competitivo do mercado de testes de ponto de cuidado molecular de África (utilizando NAAT) fornece detalhes sobre o concorrente. Os componentes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença em África, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, diretrizes regulamentares, análise de marca, aprovações de produtos, carga útil do produto, domínio da aplicação, curva de segurança da tecnologia. Os pontos de dados acima estão apenas relacionados com o foco das empresas no mercado africano de testes de ponto de atendimento molecular (utilizando NAAT).
Alguns dos principais players que operam no mercado de testes moleculares de ponto de cuidado de África (utilizando NAAT) são a Abbott, SD Biosensor, Thermo Fisher Scientific Inc., INC., bioMérieux SA, Danaher, Hologic, Inc., Seegene Inc., Sysmex Corporation, F Hoffmann-La Roche Ltd e outros.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 DISTRIBUTION CHANNEL LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTERS FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 ANNUAL TEST VOLUME: FOR ALL COUNTRIES
4.3.1 CEPHEID
4.3.2 THERMO FISHER SCIENTIFIC INC.
4.3.3 HOLOGIC, INC.
4.3.4 BD
4.3.5 F. HOFFMANN-LA ROCHE LTD
4.4 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY
4.5 PRICE PER POCT INSTRUMENT
4.5.1 NORTH AMERICA
4.5.2 EUROPE
4.5.3 SOUTH ASIA
4.5.4 SOUTH EAST ASIA
4.5.5 MIDDLE EAST
4.5.6 AFRICA
4.6 PRICE PER TEST
4.6.1 NORTH AMERICA
4.6.2 EUROPE
4.6.3 SOUTH ASIA
4.6.4 SOUTH EAST ASIA
4.6.5 MIDDLE EAST
4.6.6 AFRICA
4.7 MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS
4.8 MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI)
4.9 MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS
4.1 MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS
4.11 DISTRIBUTORS
4.11.1 NORTH AMERICA
4.11.2 EUROPE
4.11.3 SOUTH ASIA
4.11.4 SOUTH EAST ASIA
4.11.5 MIDDLE EAST
4.11.6 AFRICA
5 REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES
6.1.2 IMPROVING DIAGNOSIS SEEKING RATE
6.1.3 RISING TECHNOLOGICAL ADVANCEMENTS
6.1.4 RISING GERIATRIC POPULATION ACROSS GLOBE
6.1.5 RISING PREFERENCE FOR HOMECARE TESTING
6.2 RESTRAINTS
6.2.1 PRODUCT RECALLS
6.2.2 HIGH COSTS OF PRODUCTS
6.2.3 NON-AVAILABILITY OF RELEVANT AND APPROPRIATE KITS
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS
6.3.2 RISING HEALTHCARE EXPENDITURE
6.3.3 PANDEMIC OUTBREAK OF COVID-19
6.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS
6.4 CHALLENGES
6.4.1 LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES
6.4.2 LACK OF ACCESSIBILITY
7 IMPACT OF COVID-19 ON THE AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY CHAIN
7.4 KEY INITIATIVES BY MARKET PLAYERS DURING THE COVID 19
7.5 CONCLUSION:
8 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 CONSUMABLES & REAGENTS
8.3 INSTRUMENTS
8.3.1 MOBILE PLATFORM (SMALL & PORTABLE)
8.3.2 FACILITY-BASED PLATFORMS (LARGE POCT PLATFORM)
9 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION
9.1 OVERVIEW
9.2 RESPIRATORY INFECTIONS TESTING
9.2.1 COVID-19
9.2.2 FLU B
9.2.3 FLU A
9.2.4 RSV
9.2.5 TUBERCULOSIS
9.2.6 PNEUMONIA (PNEUMOCOCCAL PNEUMONIA)
9.2.7 OTHERS
9.3 SEXUALLY TRANSMITTED INFECTION (STI) TESTING
9.3.1 TV
9.3.2 CT
9.3.3 NG
9.3.4 HPV
9.3.5 HSV
9.3.6 MG
9.3.7 UU
9.3.8 MH
9.3.9 OTHERS
9.4 GASTROINTESTINAL TRACT INFECTIONS TESTING
9.4.1 GROUP B STREPTOCOCCUS
9.4.2 SHIGA TOXIN
9.4.3 H. PYLORI
9.5 OTHERS
10 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER
10.1 OVERVIEW
10.2 LABORATORIES
10.3 HOSPITAL
10.4 CLINICS
10.5 AMBULATORY CENTER
10.6 HOMECARE
10.7 ASSISTED LIVING FACILITIES
10.8 OTHERS
11 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING
11.1 OVERVIEW
11.2 PRESCRIPTION-BASED TESTING
11.3 OTC TESTING
12 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT SALES
12.3 THIRD PARTY DISTRIBUTOR
12.4 ONLINE SALES
13 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION
13.1 AFRICA
13.1.1 SOUTH AFRICA
13.1.2 KENYA
13.1.3 NIGERIA
13.1.4 REST OF AFRICA
14 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: AFRICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 DANAHER
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 THERMO FISHER SCIENTIFIC INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 HOLOGIC, INC.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 BD
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.5 F.HOFFMANN-LA-ROCHE LTD.
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENTS
16.6 ABBOTT
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENTS
16.7 BINX HEALTH, INC.
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
16.8 BIOMERIEUX SA
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENT
16.9 BIO-RAD LABORATORIES, INC.
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENTS
16.1 CO-DIAGNOSTICS, INC.
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENTS
16.11 GENMARK DIAGNOSTICS, INC
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENT
16.12 GRIFOLS, S.A.
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENT
16.13 LUCIRA HEALTH INC.
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENTS
16.14 MERIDIAN BIOSCIENCE
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENTS
16.15 OXFORD NANOPORE TECHNOLOGIES
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 PERKIN ELMER INC.
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENT
16.17 QIAGEN
16.17.1 COMPANY SNAPSHOT
16.17.2 REVENUE ANALYSIS
16.17.3 PRODUCT PORTFOLIO
16.17.4 RECENT DEVELOPMENTS
16.18 QUANTUMDX GROUP LTD.
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENTS
16.19 QUIDEL CORPORATION
16.19.1 COMPANY SNAPSHOT
16.19.2 REVENUE ANALYSIS
16.19.3 PRODUCT PORTFOLIO
16.19.4 RECENT DEVELOPMENT
16.2 RANDOX LABORATORIES LTD.
16.20.1 COMPANY SNAPSHOT
16.20.2 PRODUCT PORTFOLIO
16.20.3 RECENT DEVELOPMENTS
16.21 SD BIOSENSOR, INC.
16.21.1 COMPANY SNAPSHOT
16.21.2 PRODUCT PORTFOLIO
16.21.3 RECENT DEVELOPMENT
16.22 SEEGENE INC,
16.22.1 COMPANY SNAPSHOT
16.22.2 REVENUE ANALYSIS
16.22.3 PRODUCT PORTFOLIO
16.22.4 RECENT DEVELOPMENT
16.23 SEKISUI DIAGNOSTICS (A SUBSIDIARY OF SEKISUI MEDICAL)
16.23.1 COMPANY SNAPSHOT
16.23.2 PRODUCT PORTFOLIO
16.23.3 RECENT DEVELOPMENT
16.24 SYSMEX (A SUBSIDIARY OF SYSMEX CORPORATION
16.24.1 COMPANY SNAPSHOT
16.24.2 REVENUE ANALYSIS
16.24.3 PRODUCT PORTFOLIO
16.24.4 RECENT DEVELOPMENT
16.25 WONDFO
16.25.1 COMPANY SNAPSHOT
16.25.2 PRODUCT PORTFOLIO
16.25.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
Lista de Tabela
TABLE 1 CEPHEID: ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 2 THERMO FISHER SCIENTIFIC INC. : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 3 HOLOGIC, INC. : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 4 BD : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 5 F. HOFFMANN-LA ROCHE LTD : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 6 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY, 2020 (UNITS)
TABLE 7 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)
TABLE 8 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)
TABLE 9 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)
TABLE 10 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)
TABLE 11 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)
TABLE 12 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)
TABLE 13 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)
TABLE 14 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)
TABLE 15 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)
TABLE 16 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)
TABLE 17 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)
TABLE 18 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)
TABLE 19 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)
TABLE 20 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)
TABLE 21 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)
TABLE 22 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)
TABLE 23 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)
TABLE 24 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)
TABLE 25 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)
TABLE 26 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)
TABLE 27 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)
TABLE 28 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)
TABLE 29 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)
TABLE 30 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)
TABLE 31 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)
TABLE 32 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)
TABLE 33 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)
TABLE 34 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)
TABLE 35 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)
TABLE 36 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)
TABLE 37 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)
TABLE 38 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)
TABLE 39 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)
TABLE 40 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)
TABLE 41 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)
TABLE 42 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)
TABLE 43 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)
TABLE 44 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)
TABLE 45 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)
TABLE 46 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)
TABLE 47 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)
TABLE 48 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)
TABLE 49 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)
TABLE 50 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)
TABLE 51 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)
TABLE 52 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)
TABLE 53 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)
TABLE 54 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)
TABLE 55 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)
TABLE 56 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)
TABLE 57 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)
TABLE 58 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)
TABLE 59 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)
TABLE 60 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)
TABLE 61 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)
TABLE 62 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)
TABLE 63 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)
TABLE 64 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)
TABLE 65 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)
TABLE 66 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)
TABLE 67 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)
TABLE 68 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)
TABLE 69 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)
TABLE 70 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)
TABLE 71 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)
TABLE 72 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)
TABLE 73 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)
TABLE 74 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)
TABLE 75 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)
TABLE 76 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)
TABLE 77 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)
TABLE 78 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)
TABLE 79 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)
TABLE 80 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)
TABLE 81 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)
TABLE 82 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)
TABLE 83 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)
TABLE 84 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)
TABLE 85 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)
TABLE 86 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)
TABLE 87 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)
TABLE 88 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)
TABLE 89 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)
TABLE 90 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)
TABLE 91 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)
TABLE 92 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)
TABLE 93 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)
TABLE 94 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)
TABLE 95 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)
TABLE 96 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)
TABLE 97 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)
TABLE 98 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)
TABLE 99 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)
TABLE 100 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)
TABLE 101 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)
TABLE 102 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)
TABLE 103 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)
TABLE 104 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)
TABLE 105 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)
TABLE 106 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)
TABLE 107 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)
TABLE 108 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)
TABLE 109 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)
TABLE 110 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)
TABLE 111 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)
TABLE 112 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)
TABLE 113 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)
TABLE 114 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)
TABLE 115 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 116 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 117 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 118 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 119 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 120 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 121 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 122 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 123 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 124 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 125 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 126 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 127 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 128 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 129 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 130 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 131 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 132 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 133 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 134 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 135 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 136 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 137 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 138 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)
TABLE 139 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)
TABLE 140 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)
TABLE 141 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)
TABLE 142 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)
TABLE 143 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)
TABLE 144 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)
TABLE 145 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)
TABLE 146 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)
TABLE 147 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)
TABLE 148 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)
TABLE 149 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)
TABLE 150 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)
TABLE 151 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)
TABLE 152 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)
TABLE 153 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)
TABLE 154 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)
TABLE 155 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)
TABLE 156 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)
TABLE 157 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)
TABLE 158 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)
TABLE 159 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)
TABLE 160 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)
TABLE 161 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)
TABLE 162 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)
TABLE 163 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)
TABLE 164 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)
TABLE 165 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)
TABLE 166 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)
TABLE 167 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)
TABLE 168 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)
TABLE 169 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)
TABLE 170 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)
TABLE 171 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)
TABLE 172 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)
TABLE 173 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)
TABLE 174 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)
TABLE 175 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)
TABLE 176 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)
TABLE 177 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)
TABLE 178 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)
TABLE 179 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)
TABLE 180 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)
TABLE 181 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)
TABLE 182 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)
TABLE 183 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)
TABLE 184 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)
TABLE 185 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)
TABLE 186 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)
TABLE 187 NORTH AMERICA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 188 NORTH AMERICA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 189 EUROPE MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 190 EUROPE MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 191 SOUTH ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 192 SOUTH ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 193 SOUTH EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 194 SOUTH EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 195 MIDDLE EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 196 MIDDLE EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 197 AFRICA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 198 AFRICA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 199 NORTH AMERICA MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 200 EUROPE MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 201 SOUTH ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 202 SOUTH EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 203 MIDDLE EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 204 AFRICA MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 205 NORTH AMERICA MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 206 EUROPE MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 207 SOUTH ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 208 SOUTH EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 209 MIDDLE EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 210 AFRICA MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 211 NORTH AMERICA MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 212 EUROPE MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 213 SOUTH ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 214 SOUTH EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 215 MIDDLE EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 216 AFRICA MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )
TABLE 217 DISTRIBUTORS ACROSS NORTH AMERICA
TABLE 218 DISTRIBUTORS ACROSS EUROPE
TABLE 219 DISTRIBUTORS ACROSS SOUTH ASIA
TABLE 220 DISTRIBUTORS ACROSS SOUTH EAST ASIA
TABLE 221 DISTRIBUTORS ACROSS MIDDLE EAST
TABLE 222 DISTRIBUTORS ACROSS AFRICA
TABLE 223 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 224 AFRICA CONSUMABLES & REAGENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 225 AFRICA PEDIATRIC IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 226 AFRICA INSTRUMENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 227 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 228 AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 229 AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 230 AFRICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 231 AFRICA SEXUALLY TRANSMITTED IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 232 AFRICA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 233 AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 234 AFRICA OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 235 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 236 AFRICA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 237 AFRICA HOSPITAL IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 238 AFRICA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 239 AFRICA AMBULATORY CENTER IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 240 AFRICA HOME CARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 241 AFRICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 242 AFRICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 243 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 244 AFRICA PRESCRIPTION-BASED TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 245 AFRICA OTC TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 246 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 247 AFRICA DIRECT SALES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 248 AFRICA THIRD PARTY DISTRIBUTOR IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 249 AFRICA ONLINE SALE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 250 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 251 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 252 AFRICA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 253 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 254 AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 255 AFRICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 256 AFRICA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 257 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 258 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 259 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 260 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 261 SOUTH AFRICA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 262 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 263 SOUTH AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 264 SOUTH AFRICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 265 SOUTH AFRICAGASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 266 SOUTH AFRICAMOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 267 SOUTH AFRICAMOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 268 SOUTH AFRICAMOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 269 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 270 KENYA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 271 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 272 KENYA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 273 KENYA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 274 KENYA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 275 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 276 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 277 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 278 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 279 NIGERIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 280 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 281 NIGERIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 282 NIGERIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 283 NIGERIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 284 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 285 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 286 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 287 REST OF AFRICA & AFRCIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
Lista de Figura
FIGURE 1 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SEGMENTATION
FIGURE 2 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DATA TRIANGULATION
FIGURE 3 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DROC ANALYSIS
FIGURE 4 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: MULTIVARIATE MODELLING
FIGURE 8 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: END USER OVERAGE GRID
FIGURE 11 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 INCREASING PREVALENCE OF CHRONIC DISEASE AND IMPROVING DIAGNOSIS SEEKING RATE ARE EXPECTED TO DRIVE THE AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 CONSUMABLES AND REAGENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET IN 2021 & 2028
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET
FIGURE 16 MEDICAL DEVICE SPENDING VS NATIONAL HEALTH EXPENDITURES, 2016
FIGURE 17 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, 2020
FIGURE 18 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, 2021-2028 (USD MILLION)
FIGURE 19 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, CAGR (2021-2028)
FIGURE 20 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 21 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, 2020
FIGURE 22 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, 2021-2028 (USD MILLION)
FIGURE 23 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, CAGR (2021-2028)
FIGURE 24 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 25 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, 2020
FIGURE 26 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, 2021-2028 (USD MILLION)
FIGURE 27 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, CAGR (2021-2028)
FIGURE 28 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, LIFELINE CURVE
FIGURE 29 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, 2020
FIGURE 30 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, 2021-2028 (USD MILLION)
FIGURE 31 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, CAGR (2021-2028)
FIGURE 32 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, LIFELINE CURVE
FIGURE 33 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 34 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 35 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 36 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 37 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)
FIGURE 38 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)
FIGURE 39 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 40 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 41 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)
FIGURE 42 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY SHARE 2020 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.